Transdermal delivery of repaglinide from solid lipid nanoparticles in diabetic rats: In vitro and in vivo studies

Journal of Pharmaceutical Sciences and Research

Volumn 3, Issue 3, 2011, Pages 1077-1081

  Vijayan, V ^a   Jayachandran, E ^b   Anburaj, J ^c   Rao, D Srnivasa ^a   Jayaraj Kumar, K ^d  

^a KCReddy Institute of Pharmaceutical Sciences   (India)

^b SCS College of Pharmacy   (India)

^c ARULMIGU KALASALINGAM COLLEGE OF PHARMACY   (India)

^d Rao's College of Pharmacy   (India)

Author keywords

Diabetic; In vivo studies; Repaglinide; Solid lipid nanoparticles; Transdermal patches

Indexed keywords

GLUCOSE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PLACEBO; POLYSORBATE 80; REPAGLINIDE; SOLID LIPID NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISPERSION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; EX VIVO STUDY; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; MALE; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; RAT; SCANNING ELECTRON MICROSCOPY; SKIN PERMEABILITY; STREPTOZOCIN DIABETES; SUSTAINED DRUG RELEASE; TRANSDERMAL PATCH; ZETA POTENTIAL;

EID: 79953096074     PISSN: None     EISSN: 09751459     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Chetty, D.J, Chein, Y.W., 1998.Novel methods of insulin delivery: an update. Crit rev ther Drug Carrier Syst.15, 629-670.
2. Tachibana K., 1992. Transdermal delivery of insulin to alloxan-diabetic rabbits by ultrasound exposure. Pharm Res. 9,952-954.
3. Mugumu Higaki, M.D., 2006. Transdermal delivery of Caco3- Nanoparticles Containing Insulin, Diabetes Technology & Therapeutics. 8, (3), 369-374.
4. Hoffman A, Ziv E., 1997, Pharmokinetic considerations of new insulin formulations and routes of administration. Clin Pharmacokinet. 33, 285-301.
5. Kari B., 1986.Control of blood glucose levels in alloxan-diabetic rabbits by iontophoresis of insulin. Diabetes. 35,217-221.
6. Rendell., 2004. Advances in diabetes for the millennium, drug therapy of type 2 diabetes MedGenMed: Medscape general medicine. 6, 3, 9.PMIDV 15647714.
7. Guo J., Ping Q., Zhang L., 2000. Transdermal delivery of insulin in mice by using lecithin vesicles as a carrier. Drug Deliv. 7,113-116.
8. Culy, C.R., Jarvis, B., 2001. Repaglanide: a review of its therapeutic use in type II diabetes mellitus. Drugs 61, 1625-1660.
9. Rizzo MR., Barbieri M., 2003. Repaglanide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study. Diabetes Metab.30:81-89.
10. Ogiso T, Nishioka S., 1996. Dissociation of insulin oligomers and enhancement of percutaneous absorption of insulin. Biol Pharm Bull, 19:1049-1054.
11. King MJ., Badea I., Solomon J.,2002. Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats. Diabetes Technol Ther, 4:479-488.
12. Mutalik, S., Udupa, N., 2005. Formulation development, in vitro and in vivo evaluation of membrane controlled transdermal systems of glibenclamide. Journal of Pharmacy and Pharmaceutical Sciences, 1, 26-38.